Exhibit 99.1

Contact:		Jake Elguicze
		Vice President Investor Relations
		610-948-2836

FOR IMMEDIATE RELEASE		April 26, 2011

TELEFLEX REPORTS FIRST QUARTER 2011 RESULTS

Revenue from continuing operations of $388.7 million — up 6% as reported and on a constant currency basis

GAAP diluted earnings per share from continuing operations of $0.42; $0.96 on an adjusted basis

Limerick, PA — Teleflex Incorporated (NYSE: TFX), a leading, global provider of medical technology products, today reported financial results for the three months ended March 27, 2011.

First quarter 2011 net revenues were $388.7 million, an increase of 6% over the prior year period. Excluding the impact of foreign exchange, first quarter 2011 net revenues increased 6% over the prior year period.

First quarter 2011 GAAP diluted earnings per share from continuing operations was $0.42, a decrease of 49% over the prior year period. First quarter 2011 adjusted diluted earnings per share from continuing operations (previously referred to as “adjusted diluted cash earnings per share from continuing operations”) was $0.96, a decrease of 5% over the prior year period.

“In the first quarter, our team made significant progress towards completing our transition to a global medical technology leader and executing on our strategic plan,” said Benson Smith, Chairman, President & CEO. “We completed several transactions that allow us to redeploy resources to our core medical business, while exiting non-medical segments and reducing debt. At the same time, we increased the year over year revenue growth rate within our medical business and intend to build on the first quarter momentum during the remainder of the year.”

Added Mr. Smith, “During the quarter, we enhanced our competitive position in the medical business by acquiring the VasoNova™ VPS™ vascular positioning system, a central venous catheter tip navigation system. In March, VasoNova received 510(k) clearance from the FDA for expanded use of the VPS tip location technology as an alternative to chest x-ray or fluoroscopy in adult patients during peripherally inserted central catheter procedures. This unique confirmation technology eliminates the need for costly X-rays and revision procedures, which we believe is an important advance in the evolution of vascular access. In addition, during the quarter, we received 510(k) clearance from the FDA for our Arrow^® NextStep™ Antegrade Chronic Hemodialysis catheter, which is designed to attain long term vascular access for hemodialysis and apheresis.”

“We also reached several agreements that position us for increased medical product revenue growth as the year progresses,” continued Mr. Smith. “For example, we expanded our vascular access product offerings with a global distribution agreement for POLYSITE^® intravenous implantable infusion ports. In addition, we were awarded three new group purchasing organization (GPO) contracts and received two GPO contract extensions for a combination of vascular access, surgical, respiratory and anesthesia products. At the same time, we continue to focus resources on medical product R&D and acquiring unique technologies in order to drive future introduction of new, differentiated products designed to expand market share, increase growth opportunities and build shareholder returns.”

BUSINESS SEGMENT RESULTS

Medical Segment

First quarter 2011 net revenues were $354.0 million, an increase of 3% over the prior year period on an as reported and on a constant currency basis.

Critical Care first quarter 2011 net revenues were $237.1 million, an increase of 5% on both a reported and constant currency basis over the prior year period. The increase in revenue was due to higher sales of vascular access, respiratory and urology products.

Surgical Care first quarter 2011 net revenues were $65.0 million, an increase of 3% on both a reported and constant currency basis over the prior year period. The increase in revenue was due to higher sales of ligation, closure and chest drainage products.

Cardiac Care first quarter 2011 net revenues were $17.7 million, a decrease of 3% over the prior year period. Excluding the impact of foreign exchange, first quarter 2011 net revenues decreased 4% over the prior year period. The decrease in revenue was due to the voluntary recall of the 5800 series intra-aortic balloon catheters that was announced in December of 2010.

OEM and Development Services first quarter 2011 net revenues were $33.9 million, a decrease of 4% on both a reported and constant currency basis over the prior year period. The decrease in revenue was due to lower sales of specialty products.

		Three Months Ended								% Increase/ (Decrease)
										Constant				Foreign				Total
		March 27, 2011				March 28, 2010				Currency				Currency				Change
		(Dollars in millions)
Critical Care		$	237.1			$	225.9				5	%			—				5	%
Surgical Care			65.0				63.1				3	%			—				3	%
Cardiac Care			17.7				18.3				(4	%)			1	%			(3	%)
OEM			33.9				35.3				(4	%)			—				(4	%)
Other			0.3				0.9				(67	%)			—				(67	%)
Total		$	354.0			$	343.5				3	%			—				3	%

Non-Core Assets

First quarter 2011 net revenues were $34.7 million, an increase of 46% over the prior year period. Excluding the impact of foreign exchange, first quarter 2011 net revenues increased 42% over the prior year period. The increase in revenue was due to higher sales of cargo spares and repairs products.

BALANCE SHEET HIGHLIGHTS

Cash and cash equivalents at March 27, 2011 were $202.3 million compared to $208.5 million at December 31, 2010, a decrease of 3%.

Net accounts receivable at March 27, 2011 were $289.8 million compared to $294.2 million at December 31, 2010, a decrease of 1%.

Net inventories at March 27, 2011 were $319.9 million compared to $338.6 million at December 31, 2010, a decrease of 6%.

Net debt obligations at March 27, 2011 were $727.4 million compared to $788.6 million at December 31, 2010, a decrease of 8%.

2011 OUTLOOK

In the first quarter of 2011, management approved a plan to sell the Company’s Aerospace businesses. The Company has begun actively marketing the cargo container business, while it continues to serve its customers and provide appropriate transition. For financial statement purposes, the assets, liabilities, results of operations and cash flows of this business have been segregated from those of continuing operations and are presented in the Company’s condensed consolidated financial statements as discontinued operations. The accompanying condensed consolidated financial statements have been reclassified to reflect this presentation.

The cargo container business was expected to contribute annual revenue, adjusted earnings per share, and cash flow from operations of $50 million, $0.05 per diluted share, and $5 million, respectively. As a result, the Company is adjusting its financial estimates with respect to forecasted 2011 revenue from a range of $1.625 billion to $1.655 billion to a range of $1.575 billion to $1.605 billion; adjusted earnings per share from a range of $4.50 to $4.70 to a range of $4.45 to $4.65; and cash flow from continuing operations from $230 million to $225 million.

2011 Outlook earnings per share reconciliation

		Low				High
Diluted earnings per share attributable to common shareholders		$	3.15			$	3.35
Special items, net of tax		$	0.45			$	0.45
Intangible amortization expense, net of tax		$	0.70			$	0.70
Amortization of debt discount on convertible notes, net of tax		$	0.15			$	0.15
Adjusted diluted earnings per share1		$	4.45			$	4.65

LONGER-TERM GROWTH AND PROFITABILITY OBJECTIVES

With the portfolio transition to healthcare largely complete, we have increased our focus on delivering long-term growth and profitability. As such, we are targeting the achievement of the following objectives within the next five years:

	•		Consolidated revenue growth of approximately 5%
	•		Consolidated gross margins of approximately 55%

	•		Consolidated research and development expense of approximately 5%
	•		Consolidated operating margins of approximately 25%
	•		Return on equity of approximately 15%

We believe revenue growth will be achieved through the introduction of new products and product line extensions, expansion of our geographic reach, leveraging our existing distribution channels, further investment in our global sales and marketing groups and select acquisitions that enhance or expedite our development initiatives and our ability to increase our market share. We anticipate that margin expansion will be achieved through various initiatives which may include: consolidation of distribution facilities; efficiencies gained from the reduction of third-party vendors; consolidation and productivity improvements of manufacturing locations and customer service; and further initiatives to realize increased efficiencies with respect to general and administrative expenses. We expect that some of these benefits to be offset by increases in spending in research and development.

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

As previously announced, Teleflex will comment on its first quarter 2011 results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company’s website at www.teleflex.com and the accompanying presentation will be posted prior to the call. An audio replay will be available until May 3, 2011, 12:00pm (ET), by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 32439030.

ADDITIONAL NOTES

Constant currency revenue and growth exclude the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Constant currency revenue and growth include activity of a purchased company beyond the initial twelve months after the date of acquisition.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Segment results and commentary exclude the impact of discontinued operations, items included in restructuring and impairment charges, and losses and other charges set forth in the condensed consolidated statements of income.

NOTES ON NON-GAAP FINANCIAL MEASURES

This press release includes certain non-GAAP financial measures. These measures include adjusted diluted earnings per share (previously referred to as “adjusted diluted cash earnings per share”), which excludes the effect of charges associated with our restructuring programs and asset impairments, losses and other charges related to refinancing transactions, costs associated with severance payments and benefits to be provided to our former chief executive officer, intangible amortization expense and the amortization of debt discount on convertible notes; and constant currency revenue and growth, which exclude the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Consistent with past practice, adjusted diluted earnings per share has not been adjusted to exclude the benefit resulting from the forfeiture of equity awards. Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. In addition, management uses these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are set forth below.

RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS

		Three Months Ended				Three Months Ended
		March 27, 2011				March 28, 2010
		(Dollars in thousands, except per share)
Income and diluted earnings per share attributable to common shareholders		$	17,118			$	33,234
Restructuring and impairment charges			595				463
Tax benefit			(225	)			(115	)
Restructuring and impairment charges, net of tax			370				348
		$	0.01			$	0.01
Losses and other charges (A)			20,097				—
Tax benefit			(7,304	)			—
Losses and other charges, net of tax			12,793				—
		$	0.32				—
Amortization of debt discount on convertible notes			2,363				—
Tax benefit			(862	)			—
Amortization of debt discount on convertible notes, net of tax			1,501				—
		$	0.04				—
Intangible amortization expense			11,220				10,732
Tax benefit			(4,094	)			(3,901	)
Intangible amortization expense, net of tax			7,126				6,831
		$	0.18			$	0.17
Adjusted income and diluted earnings per share		$	38,908			$	40,413
		$	0.96			$	1.01

RECONCILIATION OF CASH FLOW FROM OPERATIONS

		Three Months Ended				Three Months Ended
		March 27, 2011				March 28, 2010
		(Dollars in thousands)
Cash flow from operations as reported		$	14,062			$	34,377
Add: Impact of the adoption of the amendment to Accounting Standards Codification topic 860 “Transfers and Servicing”			—				39,700
Less: Tax refund on sale of ATI business			—				49,418
Adjusted cash flow from operations		$	14,062			$	24,659

RECONCILIATION OF NET DEBT OBLIGATIONS

		March 27, 2011				December 31, 2010
		(Dollars in thousands)
Note payable and current portion of long-term borrowings		$	29,700			$	103,711
Long term borrowings			822,473				813,409
Unamortized debt discount			77,527				79,891
Total debt obligations			929,700				997,011
Less: cash and cash equivalents			202,298				208,452
Net debt obligations		$	727,402			$	788,559

ABOUT TELEFLEX INCORPORATED

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 130 countries. The company also has niche businesses which produce specialty engineered products for the aerospace market. For additional information about Teleflex please refer to www.teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, statements relating to forecasted 2011 total revenue and adjusted earnings per share; our longer-term growth and profitability objectives with respect to consolidated annual organic revenue growth, consolidated gross margins, consolidated research and development expense and consolidated operating margins; our expectations that revenue growth will be achieved through the introduction of new products and product line extensions, expansion of our geographic reach, leveraging our existing distribution channels, further investment in our global sales and marketing groups and select acquisitions that enhance or expedite our development initiatives and our ability to increase our market share; our anticipation that margin expansion will be achieved through various initiatives which may include: consolidation of distribution facilities; efficiencies gained from the reduction of third-party vendors; consolidation and productivity improvements of manufacturing locations and customer service; and further initiatives to realize increased efficiencies with respect to general and administrative expenses; and our expectation that increased spending in research and development will offset some of the benefits we expect to achieve. Actual results could differ materially from those in the forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; changes in the reimbursement practices of third party payors; our ability to realize efficiencies and to execute on our strategic initiatives; changes in material costs and surcharges; market acceptance and unanticipated difficulties in connection with the introduction of new products and product line extensions; product recalls; unanticipated difficulties in connection with the consolidation of manufacturing and administrative functions; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses, including unanticipated costs and difficulties in connection with the resolution of issues related to the FDA corporate warning letter issued to Arrow; the impact of government healthcare reform legislation; our ability to meet our debt obligations; changes in general and international economic conditions; and other factors described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

###

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

		Three Months Ended
		March 27,				March 28,
		2011				2010
		(Dollars and shares in thousands,
		except per share)
Net revenues		$	388,658			$	367,332
Cost of goods sold			212,620				190,435
Gross profit			176,038				176,897
Selling, general and administrative expenses			109,831				100,568
Research and development expenses			11,038				9,311
Restructuring and other impairment charges			595				463
Income from continuing operations before interest, loss on extinguishments of debt and taxes			54,574				66,555
Interest expense			16,157				18,994
Interest income			(106	)			(206	)
Loss on extinguishments of debt			14,597				—
Income from continuing operations before taxes			23,926				47,767
Taxes on income from continuing operations			6,426				14,247
Income from continuing operations			17,500				33,520
Operating income from discontinued operations (including gain on disposal of $56,773 and $9,737, respectively)			58,857				13,280
Taxes (benefit) on income from discontinued operations			(1,837	)			8,842
Income from discontinued operations			60,694				4,438
Net income			78,194				37,958
Less: Net income attributable to noncontrolling interest			382				286
Net income attributable to common shareholders		$	77,812			$	37,672
Earnings per share available to common shareholders:
Basic:
Income from continuing operations		$	0.43			$	0.84
Income from discontinued operations		$	1.52			$	0.11
Net income		$	1.94			$	0.95
Diluted:
Income from continuing operations		$	0.42			$	0.83
Income from discontinued operations		$	1.50			$	0.11
Net income		$	1.92			$	0.94
Dividends per share		$	0.34			$	0.34
Weighted average common shares outstanding:
Basic			40,057				39,791
Diluted			40,424				40,199
Amounts attributable to common shareholders:
Income from continuing operations, net of tax		$	17,118			$	33,234
Income from discontinued operations, net of tax			60,694				4,438
Net income		$	77,812			$	37,672

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

		March 27,				December 31,
		2011				2010
		(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents		$	202,298			$	208,452
Accounts receivable, net			289,788				294,196
Inventories, net			319,905				338,598
Prepaid expenses and other current assets			29,019				28,831
Income taxes receivable			10,392				3,888
Deferred tax assets			34,351				39,309
Assets held for sale			40,165				7,959
Total current assets			925,918				921,233
Property, plant and equipment, net			274,328				287,705
Goodwill			1,468,990				1,442,411
Intangible assets, net			927,636				918,522
Investments in affiliates			4,723				4,899
Deferred tax assets			370				358
Other assets			76,838				68,027
Total assets		$	3,678,803			$	3,643,155
LIABILITIES AND EQUITY
Current liabilities
Current borrowings		$	29,700			$	103,711
Accounts payable			82,675				84,846
Accrued expenses			116,577				117,488
Payroll and benefit-related liabilities			67,626				71,418
Derivative liabilities			15,315				15,634
Accrued interest			8,952				18,347
Income taxes payable			4,630				4,886
Deferred tax liabilities			4,802				4,433
Liabilities held for sale			11,629				—
Total current liabilities			341,906				420,763
Long-term borrowings			822,473				813,409
Deferred tax liabilities			387,001				370,819
Pension and postretirement benefit liabilities			117,590				141,769
Noncurrent liability for uncertain tax positions			73,697				62,602
Other liabilities			47,148				46,515
Total liabilities			1,789,815				1,855,877
Commitments and contingencies
Total common shareholders’ equity			1,884,710				1,783,376
Noncontrolling interest			4,278				3,902
Total equity			1,888,988				1,787,278
Total liabilities and equity		$	3,678,803			$	3,643,155

TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

		Three Months Ended
		March 27, 2011				March 28, 2010
		(Dollars in thousands)
Cash Flows from Operating Activities of Continuing Operations:
Net income		$	78,194			$	37,958
Adjustments to reconcile net income to net cash provided by operating activities:
Income from discontinued operations			(60,694	)			(4,438	)
Depreciation expense			10,849				11,274
Amortization expense of intangible assets			11,220				10,731
Amortization expense of deferred financing costs and debt discount			3,300				945
Loss on extinguishments of debt			14,597				—
Stock-based compensation			(1,055	)			1,695
Deferred income taxes, net			(1,701	)			10,130
Other			903				444
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable			(20,951	)			(43,023	)
Inventories			(10,656	)			493
Prepaid expenses and other current assets			(1,032	)			(1,914	)
Accounts payable and accrued expenses			(8,189	)			(33,777	)
Income taxes receivable and payable, net			(723	)			43,859
Net cash provided by operating activities from continuing operations			14,062				34,377
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment			(6,444	)			(6,737	)
Proceeds from sales of businesses and assets, net of cash sold			101,600				24,750
Payments for businesses and intangibles acquired, net of cash acquired			(30,570	)			(81	)
Net cash provided by investing activities from continuing operations			64,586				17,932
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings			265,000				—
Reduction in long-term borrowings			(330,800	)			(51,090	)
Increase in notes payable and current borrowings			—				39,700
Proceeds from stock compensation plans			6,764				3,670
Dividends			(13,614	)			(13,536	)
Debt extinguishment, issuance and amendment fees			(14,838	)			—
Net cash used in financing activities from continuing operations			(87,488	)			(21,256	)
Cash Flows from Discontinued Operations:
Net cash used in operating activities			(5,109	)			(3,314	)
Net cash used in investing activities			(249	)			(611	)
Net cash used in discontinued operations			(5,358	)			(3,925	)
Effect of exchange rate changes on cash and cash equivalents			8,044				(4,714	)
Net (decrease) increase in cash and cash equivalents			(6,154	)			22,414
Cash and cash equivalents at the beginning of the period			208,452				188,305
Cash and cash equivalents at the end of the period		$	202,298			$	210,719

Information about continuing operations by business segment is as follows:

		Three Months Ended
		March 27,				March 28,
		2011				2010
		(Dollars in thousands)
Segment data:
Medical		$	354,004			$	343,537
Aerospace			34,654				23,795
Segment net revenues		$	388,658			$	367,332
Medical		$	60,537			$	73,498
Aerospace			4,986				1,171
Segment operating profit			65,523				74,669
Less: Corporate expenses			10,736				7,937
Restructuring and impairment charges			595				463
Noncontrolling interest			(382	)			(286	)
Income from continuing operations before interest, loss on extinguishments of debt and taxes		$	54,574			$	66,555